sufugolix (, ) (developmental code name tak-013) is a non-peptide, orally-active, selective antagonist of the gonadotropin-releasing hormone receptor (gnrhr) ( = 0.1 and 0.06 nm for affinity and "in vitro" inhibition, respectively). it was under development by takeda for the treatment of endometriosis and uterine leiomyoma and reached phase ii clinical trials for both of these indications, but was subsequently discontinued. it seems to have been supplanted by relugolix (tak-385), which is also under development by takeda for the treatment of these conditions and has a more favorable drug profile (including reduced cytochrome p450 inhibition and improved "in vivo" gnrhr antagonistic activity) in comparison.